for TECENTRIQ Hybreza[™] (atezolizumab/hyaluronidase-tqjs)

SAMPLE CODING

Malignant Melanoma

ТҮРЕ	CODE		DESCRIPTION
Diagnosis: ICD-10-CM	C43.0*-C43.9		Malignant melanoma of skin, by site
Drug: HCPCS	J9024		Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
HCPCS: Modifier [†]	JZ		Zero drug amount discarded/not administered to any patient
Drug: NDC	10-digit	11-digit	
Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.	50242-933-01	50242-0933-01	1,875 mg atezolizumab and 30,000 units hyaluronidase per 15 mL (125 mg/2,000 units per mL) solution in a single-dose vial
Administration procedures: CPT	96401		Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code; NOS=Not Otherwise Specified.

*This range of codes does not include melanoma in situ (D03.-), malignant melanoma of the skin of genital organs (C51–C52, C60.-, C63.-), Merkel cell carcinoma (C4A.-), malignant neoplasm of vermilion border of lip (C00.0–C00.2), malignant neoplasm of the anus NOS (C21.0), malignant neoplasm of scrotum (C63.2); plus, for melanoma of sites other than the skin (not previously specified), code to the malignant neoplasm of that site.

[†]The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

TECENTRIQ HYBREZA™ is a trademark of Genentech, Inc.

Please see full <u>Prescribing Information</u> for Important Safety Information.